Literature DB >> 1709946

Antibody response to serotype-specific and cross-reactive neutralization epitopes on VP4 and VP7 after rotavirus infection or vaccination.

K Taniguchi1, T Urasawa, N Kobayashi, M U Ahmed, N Adachi, S Chiba, S Urasawa.   

Abstract

By using a competitive solid-phase immunoassay with serotype-specific and cross-reactive neutralizing monoclonal antibodies directed at VP4 and VP7, we tested the antibody responses to some neutralization epitopes on VP4 and VP7 in individuals infected or vaccinated with rotavirus. Antibody responses to VP7 epitopes of the infecting serotype of virus were found at a high frequency in both infants and children. In contrast, antibody responses to VP4 and heterotypic VP7 were observed only when the individuals possessed antibodies to any serotype of rotavirus in their acute-phase or prevaccination sera.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1709946      PMCID： PMC269805          DOI： 10.1128/jcm.29.3.483-487.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  31 in total

1.  Analysis of the newly identified neutralization epitopes on VP7 of human rotavirus serotype 1.

Authors:  N Kobayashi; K Taniguchi; S Urasawa
Journal:  J Gen Virol       Date:  1991-01       Impact factor: 3.891

2.  Original antigenic sin at the cellular level. II. Specificity of the antibodies produced by individual cells.

Authors:  S Deutsch; M A Vinit; A E Bussard
Journal:  Eur J Immunol       Date:  1973-04       Impact factor: 5.532

3.  Sequence of the fourth gene of human rotaviruses recovered from asymptomatic or symptomatic infections.

Authors:  M Gorziglia; K Green; K Nishikawa; K Taniguchi; R Jones; A Z Kapikian; R M Chanock
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

4.  Serotype determination of human rotavirus isolates and antibody prevalence in pediatric population in Hokkaido, Japan.

Authors:  S Urasawa; T Urasawa; K Taniguchi; S Chiba
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

5.  Human rotavirus studies in volunteers: determination of infectious dose and serological response to infection.

Authors:  R L Ward; D I Bernstein; E C Young; J R Sherwood; D R Knowlton; G M Schiff
Journal:  J Infect Dis       Date:  1986-11       Impact factor: 5.226

6.  Serum antibody responses to individual viral polypeptides in human rotavirus infections.

Authors:  L Svensson; H Sheshberadaran; S Vene; E Norrby; M Grandien; G Wadell
Journal:  J Gen Virol       Date:  1987-03       Impact factor: 3.891

7.  Independent segregation of two antigenic specificities (VP3 and VP7) involved in neutralization of rotavirus infectivity.

Authors:  Y Hoshino; M M Sereno; K Midthun; J Flores; A Z Kapikian; R M Chanock
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

8.  Antigenic and genetic analyses of human rotavirus with dual subgroup specificity.

Authors:  T Urasawa; K Taniguchi; N Kobayashi; F Wakasugi; I Oishi; Y Minekawa; M Oseto; M U Ahmed; S Urasawa
Journal:  J Clin Microbiol       Date:  1990-12       Impact factor: 5.948

9.  Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season.

Authors:  H F Clark; F E Borian; L M Bell; K Modesto; V Gouvea; S A Plotkin
Journal:  J Infect Dis       Date:  1988-09       Impact factor: 5.226

10.  Identification of operationally overlapping and independent cross-reactive neutralization regions on human rotavirus VP4.

Authors:  N Kobayashi; K Taniguchi; S Urasawa
Journal:  J Gen Virol       Date:  1990-11       Impact factor: 3.891
View more
  12 in total

1.  Isolation of human monoclonal antibodies that neutralize human rotavirus.

Authors:  Kyoko Higo-Moriguchi; Yasushi Akahori; Yoshitaka Iba; Yoshikazu Kurosawa; Koki Taniguchi
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

2.  Serotype specificity of the neutralizing-antibody response induced by the individual surface proteins of rotavirus in natural infections of young children.

Authors:  G Menchaca; L Padilla-Noriega; M Méndez-Toss; J F Contreras; F I Puerto; H Guiscafré; F Mota; I Herrera; R Cedillo; O Muñoz; R Ward; Y Hoshino; S López; C F Arias
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

3.  Quantification of systemic and local immune responses to individual rotavirus proteins during rotavirus infection in mice.

Authors:  S Ishida; N Feng; B Tang; J M Gilbert; H B Greenberg
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

4.  Full genome characterization of human G3P[6] and G3P[9] rotavirus strains in Lebanon.

Authors:  Nischay Mishra; Lina Reslan; Mohsen El-Husseini; Hawraa Raoof; Marc Finianos; Cheng Guo; Riddhi Thakkar; Adlette Inati; Ghassan Dbaibo; W Ian Lipkin; Hassan Zaraket
Journal:  Infect Genet Evol       Date:  2019-12-05       Impact factor: 3.342

5.  VP4-specific intestinal antibody response to rotavirus in a murine model of heterotypic infection.

Authors:  R D Shaw; W S Groene; E R Mackow; A A Merchant; E H Cheng
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

6.  Resistance to rotavirus infection in adult volunteers challenged with a virulent G1P1A[8] virus correlated with serum immunoglobulin G antibodies to homotypic viral proteins 7 and 4.

Authors:  Lijuan Yuan; Shinjiro Honma; Inyoung Kim; Albert Z Kapikian; Yasutaka Hoshino
Journal:  J Infect Dis       Date:  2009-11-01       Impact factor: 5.226

7.  Serum IgA immune response to individual rotavirus polypeptides in young children with rotavirus infection.

Authors:  K Johansen; L Granqvist; K Karlén; G Stintzing; I Uhnoo; L Svensson
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

8.  Characterization of serum antibody responses to natural rotavirus infections in children by VP7-specific epitope-blocking assays.

Authors:  D O Matson; M L O'Ryan; L K Pickering; S Chiba; S Nakata; P Raj; M K Estes
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

9.  Humoral immune responses to VP4 and its cleavage products VP5* and VP8* in infants vaccinated with rhesus rotavirus.

Authors:  L Padilla-Noriega; L Fiore; M B Rennels; G A Losonsky; E R Mackow; H B Greenberg
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

10.  Neutralizing antibody immune response in children with primary and secondary rotavirus infections.

Authors:  C F Arias; S López; J D Mascarenhas; P Romero; P Cano; Y B Gabbay; R B de Freitas; A C Linhares
Journal:  Clin Diagn Lab Immunol       Date:  1994-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.